Acadia Pharmaceuticals (ACAD) sees Significant Insider Selling

Wednesday, January 31, 2018 10:15 PM ET

Acadia Pharmaceuticals (ACAD) sees Significant Insider Selling

There was a substantial sale of shares of Acadia Pharmaceuticals by an insider today, as indicated in a form 4 document filed with the SEC. One insider — Glenn Baity, Officer — disposed of 36,558 shares in the company having a market value of approximately $1,184,055. This is the first insider buy/sell trade in the past 90 days.

The level of buy-sell trades at Acadia Pharmaceuticals is close to that of the 191 member peer company average. The Biotechnology & Medical Research peer group saw 169 buy/sell trades during this period for an average of 0.9 transactions per company. However, trading at Acadia Pharmaceuticals represents a lower number of shares per transaction. Within the peer group there were 11,218,226 shares purchased and 12,872,269 shares sold with company insiders having sold 9,787 shares on average over this time period.

In determining significant insider buying and selling, trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data obtained to evaluate and write this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.